Until a year ago, the term “social distancing” wasn’t in the national lexicon and wearing masks was not the norm. But the COVID-19 pandemic changed our behaviors swiftly and often, from staying home to “flattening the curve” to donating meals to hospital workers to searching for vaccination appointments.
We learned to access work, school and entertainment via Zoom and other virtual platforms. Restaurants adapted to takeout models and, along with other businesses, have ping-ponged among various modes of operation as coronavirus cases have swelled and ebbed.
As we mark the anniversary of the first life-altering pandemic restrictions, the
La Jolla Light looks back at the past whirlwind year of COVID-19.
La Jolla News Nuggets: New Warwick s lease, cancer drug candidate, Parks & Beaches bylaws, more
lajollalight.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lajollalight.com Daily Mail and Mail on Sunday newspapers.
Leinco Technologies to develop new COVID-19 diagnostic tools
selectscience.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from selectscience.net Daily Mail and Mail on Sunday newspapers.
How a changing virus is reshaping scientists views on COVID-19 - By:
dailytrust.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailytrust.com Daily Mail and Mail on Sunday newspapers.
Industry News: Leinco Technologies partners with leading research organization to develop novel COVID-19 diagnostic tools
09 Mar 2021
La Jolla Institute for Immunology (LJI), one of the leading research organizations dedicated to studying the immune system announced today that it has signed a licensing agreement with Leinco Technologies, Inc., a premier developer, and manufacturer of leading-edge recombinant proteins, antibodies, and conjugates. Leinco also provides custom manufacturing services to the diagnostic and biopharmaceutical industries to leverage proprietary COVID-19 antibodies developed at LJI.
Under the terms of the agreement, Leinco will gain exclusive access to certain SARS-CoV-2 antibodies directed against the virus’ nucleocapsid (N) protein, which forms the virus’ inner shell. In addition to developing the antibodies for use in diagnostic applications based on N protein-specific antibodies, Leinco will make these antibodies commercially available as part of th